Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

DNA microarray technology and antimicrobial drug discovery.

Ivanov I, Schaab C, Planitzer S, Teichmann U, Machl A, Theml S, Meier-Ewert S, Seizinger B, Loferer H.

Pharmacogenomics. 2000 May;1(2):169-78. Review.

PMID:
11256588
2.

Advances in neurofibromatosis 2 (NF2): a workshop report.

Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovannini M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza R, McClatchey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE.

J Neurogenet. 2000 Jun;14(2):63-106. Review. No abstract available.

PMID:
10992163
3.

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.

Blankenship C, Naglich JG, Whaley JM, Seizinger B, Kley N.

Oncogene. 1999 Feb 25;18(8):1529-35.

4.

PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes.

Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B, Kley N.

Oncogene. 1999 Jan 7;18(1):127-37.

5.

The p53/IGF-1 receptor axis in the regulation of programmed cell death.

Neuberg M, Buckbinder L, Seizinger B, Kley N.

Endocrine. 1997 Aug;7(1):107-9. Review.

PMID:
9449044
6.

The p53 tumor suppressor targets a novel regulator of G protein signaling.

Buckbinder L, Velasco-Miguel S, Chen Y, Xu N, Talbott R, Gelbert L, Gao J, Seizinger BR, Gutkind JS, Kley N.

Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7868-72.

7.

A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13.

Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G, Hintz RL, Hartman ML, Seizinger BR, Larsson C, Aronin N.

J Clin Endocrinol Metab. 1997 Feb;82(2):486-92.

PMID:
9024241
8.

Chromosome 17 allelic loss and NF1-GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis.

Gómez L, Rubio MP, Martin MT, Vázquez JJ, Idoate M, Pastorfide G, Pestaña A, Seizinger BR, Barnhill RL, Castresana JS.

J Invest Dermatol. 1996 Mar;106(3):432-6.

9.

Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.

Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N, Manne V.

J Med Chem. 1996 Jan 19;39(2):353-8.

PMID:
8558502
10.

Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.

J Med Chem. 1996 Jan 5;39(1):224-36.

PMID:
8568812
11.

Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M, et al.

Hum Mutat. 1996;8(4):348-57.

PMID:
8956040
12.

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ, Testa JR.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8.

13.

Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.

Kley N, Whaley J, Seizinger BR.

Glia. 1995 Nov;15(3):297-307. Review.

PMID:
8586465
14.

Induction of the growth inhibitor IGF-binding protein 3 by p53.

Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N.

Nature. 1995 Oct 19;377(6550):646-9.

PMID:
7566179
15.

Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.

Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V.

Cancer Res. 1995 Aug 15;55(16):3569-75.

16.

Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.

Carboni JM, Yan N, Cox AD, Bustelo X, Graham SM, Lynch MJ, Weinmann R, Seizinger BR, Der CJ, Barbacid M, et al.

Oncogene. 1995 May 18;10(10):1905-13.

PMID:
7761092
17.

Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.

Takenaka I, Morin F, Seizinger BR, Kley N.

J Biol Chem. 1995 Mar 10;270(10):5405-11.

19.
20.

Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes.

Buckbinder L, Talbott R, Seizinger BR, Kley N.

Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10640-4.

21.

Genetic basis of neurological tumours.

Louis DN, Seizinger BR.

Baillieres Clin Neurol. 1994 Aug;3(2):335-52. Review.

PMID:
7952851
22.

Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, van Drunen E, Bootsma D, Koper JW, Avezaat CJ, Kley N, et al.

Am J Hum Genet. 1994 Jun;54(6):1022-9.

23.

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

Schneider J, Rubio MP, Barbazán MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS.

J Natl Cancer Inst. 1994 Jun 1;86(11):850-5.

PMID:
7910219
24.

Dinucleotide repeat polymorphism at the D3S666 locus.

Klauck SM, Yamakawa K, Seizinger BR.

Hum Mol Genet. 1994 May;3(5):840. No abstract available.

PMID:
8081379
25.

Dinucleotide repeat polymorphism at the D3S1255 locus.

Klauck SM, Whisenant E, Wood M, Drabkin HA, Seizinger BR.

Hum Mol Genet. 1994 May;3(5):840. No abstract available.

PMID:
8081378
26.

Exon scanning for mutation of the NF2 gene in schwannomas.

Jacoby LB, MacCollin M, Louis DN, Mohney T, Rubio MP, Pulaski K, Trofatter JA, Kley N, Seizinger B, Ramesh V, et al.

Hum Mol Genet. 1994 Mar;3(3):413-9.

PMID:
8012353
27.

Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types.

Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, Menon AG, Trofatter JA, Gusella JF, Seizinger BR, et al.

Nat Genet. 1994 Feb;6(2):185-92.

PMID:
8162073
28.
29.
30.
31.

Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.

Castresana JS, Rubio MP, Vázquez JJ, Idoate M, Sober AJ, Seizinger BR, Barnhill RL.

Int J Cancer. 1993 Oct 21;55(4):562-5.

PMID:
8104906
32.

NF1: a prevalent cause of tumorigenesis in human cancers?

Seizinger BR.

Nat Genet. 1993 Feb;3(2):97-9. No abstract available.

PMID:
7848376
33.

Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma.

Li FP, Decker HJ, Zbar B, Stanton VP Jr, Kovacs G, Seizinger BR, Aburatani H, Sandberg AA, Berg S, Hosoe S, Brown RS.

Ann Intern Med. 1993 Jan 15;118(2):106-11.

PMID:
8416305
34.

Comparative study of p53 gene and protein alterations in human astrocytic tumors.

Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR.

J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8.

PMID:
8381161
35.

Subsets of glioblastoma multiforme defined by molecular genetic analysis.

von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN.

Brain Pathol. 1993 Jan;3(1):19-26.

PMID:
8269081
36.

Deletions on the long arm of chromosome 17 in pilocytic astrocytoma.

von Deimling A, Louis DN, Menon AG, von Ammon K, Petersen I, Ellison D, Wiestler OD, Seizinger BR.

Acta Neuropathol. 1993;86(1):81-5.

PMID:
8103960
37.

Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study.

Louis DN, von Deimling A, Dickersin GR, Dooling EC, Seizinger BR.

Hum Pathol. 1992 Dec;23(12):1402-9.

PMID:
1468778
38.

Cytogenetic and molecular studies of a familial renal cell carcinoma.

Decker HJ, Wullich B, Whaley JM, Herrera G, Klauck SM, Sandberg AA, Yandell DW, Seizinger BR.

Cancer Genet Cytogenet. 1992 Oct 1;63(1):25-31.

PMID:
1423222
39.
40.

Anti-oncogenes and the development of tumors in the human nervous system.

Seizinger BR.

Cancer. 1992 Sep 15;70(6 Suppl):1782-7. Review.

PMID:
1516032
41.

Repression of the basal c-fos promoter by wild-type p53.

Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR.

Nucleic Acids Res. 1992 Aug 11;20(15):4083-7.

42.

A RsaI polymorphism in the ERCC2 locus.

von Deimling A, von Deimling F, Louis DN, Trofatter J, Gusella JF, Seizinger BR.

Hum Mol Genet. 1992 Aug;1(5):355. No abstract available.

PMID:
1363878
43.

Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.

von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR.

Cancer Res. 1992 Aug 1;52(15):4277-9.

44.

Molecular genetics of neurological tumours.

Chung RY, Seizinger BR.

J Med Genet. 1992 Jun;29(6):361-7. Review. No abstract available.

45.

p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.

von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR.

Cancer Res. 1992 May 15;52(10):2987-90.

46.

Predictive testing for multiple endocrine neoplasia type 1 using DNA polymorphisms.

Larsson C, Shepherd J, Nakamura Y, Blomberg C, Weber G, Werelius B, Hayward N, Teh B, Tokino T, Seizinger B.

J Clin Invest. 1992 Apr;89(4):1344-9.

47.

Genes associated with tumor suppression and growth control in the human nervous system.

Seizinger BR.

Cancer Metastasis Rev. 1991 Dec;10(4):281-7. Review.

PMID:
1786629
48.

Parental origin of chromosome 22 loss in sporadic and NF2 neuromas.

Fontaine B, Sanson M, Delattre O, Menon AG, Rouleau GA, Seizinger BR, Jewell AF, Hanson MP, Aurias A, Martuza RL, et al.

Genomics. 1991 May;10(1):280-3.

PMID:
1675196
49.

Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease.

Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J, et al.

Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2864-8.

50.

The neurofibromatosis genes: from molecular cloning to cellular function.

Menon AG, Ponder BA, Seizinger BR.

Cancer Cells. 1991 Apr;3(4):147-52. No abstract available.

PMID:
1909154

Supplemental Content

Loading ...
Support Center